Citadel Advisors’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Citadel Advisors’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-500	Closed	-$3.88K	–	15547
2023 Q3	$3.88K	Buy	+500	New	+$2.71K	﹤0.01%	13540
2023 Q1	–	Sell	-100	Closed	-$371	–	15822
2022 Q4	$371	Sell	100 -1,040	-91%	-$4.6K	﹤0.01%	14684
2022 Q3	$6K	Sell	1,140 -420	-27%	-$2.34K	﹤0.01%	12361
2022 Q2	$9K	Buy	1,560 +470	+43%	+$2.65K	﹤0.01%	12617
2022 Q1	$8K	Buy	+1,090	New	+$10.7K	﹤0.01%	13402
2021 Q4	–	Sell	-1,650	Closed	-$38K	–	15069
2021 Q3	$38K	Buy	+1,650	New	+$49.1K	﹤0.01%	13496
2021 Q2	–	Sell	-2,250	Closed	-$163K	–	14656
2021 Q1	$163K	Buy	2,250 +260	+13%	+$18.5K	﹤0.01%	11948
2020 Q4	$86K	Buy	+1,990	New	+$89.1K	﹤0.01%	10309

Other funds holding ORTX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citadel Advisors's ORTX Position: Q4 2023 in Review

Citadel Advisors sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q4 2023, closing a stake of 95,272 shares — an estimated $739K sold.

Citadel Advisors first reported a position in ORTX in Q3 2019 and held it in 17 quarters. The position peaked at $8.12M in Q2 2020. 47 funds tracked by Wall St. Rank hold ORTX as of Q4 2023.

Citadel Advisors reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q4 2023 after selling out during the quarter.
Citadel Advisors sold 95,272 Orchard Therapeutics plc American Depositary Shares shares in Q4 2023, an estimated $739K.
Citadel Advisors first reported a position in Orchard Therapeutics plc American Depositary Shares in Q3 2019 and held it in 17 quarters.
Citadel Advisors's Orchard Therapeutics plc American Depositary Shares position peaked at $8.12M in Q2 2020.
47 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.